Christopher B Rosnick1, Julie L Wetherell2, Kamila S White3, Carmen Andreescu4, David Dixon5, Eric J Lenze5. 1. Department of Psychology, Southern Illinois University Edwardsville. 2. VA San Diego Healthcare System. 3. Department of Psychology, University of Missouri-St. Louis. 4. Department of Psychiatry, University of Pittsburgh School of Medicine. 5. Department of Psychiatry, Washington University School of Medicine.
Abstract
OBJECTIVES: Elevated cortisol in stress and aging, such as has been seen in late-life anxiety disorders, is postulated to accelerate cognitive and physiological decline in this large and increasing population. Selective serotonin-reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT) are both effective treatments for generalized anxiety disorder (GAD) in older adults. On the other hand, there is very little research examining the effect of combining these therapies on peak cortisol levels. For the current analyses, we examined the effectiveness of CBT augmentation on peak cortisol levels in older adults diagnosed with GAD. METHODS: The sample consisted of 42 individuals with late-life GAD who received an acute course of the SSRI escitalopram and then entered a 16-week randomized phase. Twenty-one participants were randomized to receive 16 sessions of CBT in addition to continuing escitalopram and the remaining 21 participants continued on escitalopram without CBT. Generalized estimating equations were performed to assess the effectiveness of CBT augmentation on peak cortisol levels (30 min after waking). RESULTS:Older adults with GAD who received both escitalopram and CBT demonstrated a significant reduction in peak cortisol levels at posttreatment compared to the group who received escitalopram without CBT augmentation. CONCLUSIONS:CBT augmentation of SSRI treatment reduced peak cortisol levels for older adults with GAD. Since persistently high cortisol levels in aging are thought to increase age-related cognitive and medical problems, our findings suggest that there may be a benefit to health and cognition of CBT augmentation for late-life anxiety disorders. (c) 2016 APA, all rights reserved).
RCT Entities:
OBJECTIVES: Elevated cortisol in stress and aging, such as has been seen in late-life anxiety disorders, is postulated to accelerate cognitive and physiological decline in this large and increasing population. Selective serotonin-reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT) are both effective treatments for generalized anxiety disorder (GAD) in older adults. On the other hand, there is very little research examining the effect of combining these therapies on peak cortisol levels. For the current analyses, we examined the effectiveness of CBT augmentation on peak cortisol levels in older adults diagnosed with GAD. METHODS: The sample consisted of 42 individuals with late-life GAD who received an acute course of the SSRI escitalopram and then entered a 16-week randomized phase. Twenty-one participants were randomized to receive 16 sessions of CBT in addition to continuing escitalopram and the remaining 21 participants continued on escitalopram without CBT. Generalized estimating equations were performed to assess the effectiveness of CBT augmentation on peak cortisol levels (30 min after waking). RESULTS: Older adults with GAD who received both escitalopram and CBT demonstrated a significant reduction in peak cortisol levels at posttreatment compared to the group who received escitalopram without CBT augmentation. CONCLUSIONS: CBT augmentation of SSRI treatment reduced peak cortisol levels for older adults with GAD. Since persistently high cortisol levels in aging are thought to increase age-related cognitive and medical problems, our findings suggest that there may be a benefit to health and cognition of CBT augmentation for late-life anxiety disorders. (c) 2016 APA, all rights reserved).
Authors: M D Miller; C F Paradis; P R Houck; S Mazumdar; J A Stack; A H Rifai; B Mulsant; C F Reynolds Journal: Psychiatry Res Date: 1992-03 Impact factor: 3.222
Authors: J C Pruessner; O T Wolf; D H Hellhammer; A Buske-Kirschbaum; K von Auer; S Jobst; F Kaspers; C Kirschbaum Journal: Life Sci Date: 1997 Impact factor: 5.037
Authors: Julie Loebach Wetherell; Steven R Thorp; Thomas L Patterson; Shahrokh Golshan; Dilip V Jeste; Margaret Gatz Journal: J Psychiatr Res Date: 2004 May-Jun Impact factor: 4.791
Authors: Melinda A Stanley; J Gayle Beck; Diane M Novy; Patricia M Averill; Alan C Swann; Gretchen J Diefenbach; Derek R Hopko Journal: J Consult Clin Psychol Date: 2003-04
Authors: Julie Loebach Wetherell; Hayley S Ripperger; Michelle Voegtle; Beau M Ances; David Balota; Emily S Bower; Colin Depp; Lisa Eyler; Erin R Foster; Denise Head; Tamara Hershey; Steven Hickman; Noralinda Kamantigue; Samuel Klein; J Philip Miller; Michael D Yingling; Jeanne Nichols; Ginger E Nicol; Bruce W Patterson; Thomas L Rodebaugh; Joshua S Shimony; Abraham Snyder; Mary Stephens; Susan Tate; Mary L Uhrich; David Wing; Gregory F Wu; Eric J Lenze Journal: Clin Trials Date: 2020-06-27 Impact factor: 2.486
Authors: Murilo S Abreu; Ana Cristina V V Giacomini; Gessi Koakoski; Angelo L S Piato; Leonardo J G Barcellos Journal: PeerJ Date: 2017-05-09 Impact factor: 2.984